Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phosphogluconate dehydrogenase is a key enzyme in the oxidative branch of the pentose phosphate pathway (PPP), catalyzing the oxidative decarboxylation of 6-phosphogluconate to ribulose-5-phosphate, producing NADPH and CO₂. It is essential for generating ribulose-5-phosphate for nucleotide synthesis and NADPH required for reductive biosynthesis and antioxidative defense. Altered activity is implicated in cancer and neurodegenerative diseases, making it a potential therapeutic target.
Inhibition of 6-phosphogluconate dehydrogenase to reduce NADPH production and anabolic biosynthesis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phosphogluconate Dehydrogenase (6PGD).